Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial

Jain, Nitin; Curran, Emily; M. Iyengar, Neil; Díaz-Flores, Ernesto; Kunnavakkam, Rangesh; Popplewell, Leslie; Kirschbaum, Mark; Karrison, Theodore; P. Erba, Harry; Green, Margaret; Poiré, Xavier; Koval, Greg; Shannon, Kevin; L. Reddy, Poluru; Joseph, Loren; Atallah, Ehab; A. Dy, Philip; Thomas, Sachdev; E. Smith, Scott; Austin Doyle, L.; M. Stadler, Walter; A. Larson, Richard; Stock, Wendy; Odenike, Olatoyosi

doi:10.1158/1078-0432.ccr-13-1311

Public

Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial

Published in Clinical Cancer Research • Nov 1, 2013

Authors:

Nitin Jain

Emily Curran

Neil M. Iyengar

Abstract

PURPOSE: The clinical relevance of targeting the RAS/RAF/MEK/ERK pathway, activated in 70% to 80% of patients with acute myelogenous leukemia (AML), is unknown. EXPERIMENTAL DESIGN: Selumetinib is an oral small-molecule inhibitor of MAP-ERK kinase (MEK)-1/2. Forty-seven patients with relapsed/refrac...

Subject

Selumetinib

Medicine

MEK inhibitor

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!